{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:22:02Z","timestamp":1790698922958,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41591-026-04354-1","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:02:21Z","timestamp":1777021341000},"page":"2201-2215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8509-6165","authenticated-orcid":false,"given":"Marie-Anne","family":"Debily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3292-0939","authenticated-orcid":false,"given":"Gwenael","family":"Le Teuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kergrohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Varlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0247-080X","authenticated-orcid":false,"given":"David","family":"Castel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7088-2614","authenticated-orcid":false,"given":"Pierre","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-9807","authenticated-orcid":false,"given":"Darren","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-0058","authenticated-orcid":false,"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-7271","authenticated-orcid":false,"given":"Klas","family":"Blomgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey Brian","family":"McCowage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-8862","authenticated-orcid":false,"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dannis","family":"van Vuurden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3054-5832","authenticated-orcid":false,"given":"Elisa","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7451-7916","authenticated-orcid":false,"given":"David S.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angokai","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Puget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Beccaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Aquilina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Riffaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1311-9214","authenticated-orcid":false,"given":"Stephanie","family":"Bolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Abbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Isabelle","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"De Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-7774","authenticated-orcid":false,"given":"Nathalie","family":"Boddaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volodia","family":"Dangouloff-Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Calmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9cile","family":"Le Deley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4773-3001","authenticated-orcid":false,"given":"Jacques","family":"Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"4354_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","volume":"24","author":"S Bender","year":"2013","unstructured":"Bender, S. et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660\u2013672 (2013).","journal-title":"Cancer Cell"},{"key":"4354_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0614-1","volume":"6","author":"D Castel","year":"2018","unstructured":"Castel, D. et al. Transcriptomic and epigenetic profiling of \u2018diffuse midline gliomas, H3 K27M-mutant\u2019 discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. Acta Neuropathol. Commun. 6, 117 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"4354_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09981-6","volume":"10","author":"SU Jain","year":"2019","unstructured":"Jain, S. U. et al. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nat. Commun. 10, 2146 (2019).","journal-title":"Nat. Commun."},{"key":"4354_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40478-022-01442-4","volume":"10","author":"C Mariet","year":"2022","unstructured":"Mariet, C. et al. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis. Acta Neuropathol. Commun. 10, 137 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"4354_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251\u2013253 (2012).","journal-title":"Nat. Genet."},{"key":"4354_CR6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","volume":"340","author":"PW Lewis","year":"2013","unstructured":"Lewis, P. W. et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340, 857\u2013861 (2013).","journal-title":"Science"},{"key":"4354_CR7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00401-020-02142-w","volume":"139","author":"D Castel","year":"2020","unstructured":"Castel, D. et al. Histone H3 wild-type DIPG\/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. Acta Neuropathol. 139, 1109\u20131113 (2020).","journal-title":"Acta Neuropathol."},{"key":"4354_CR8","first-page":"119","volume":"31","author":"Y Coutel","year":"1959","unstructured":"Coutel, Y. [Infiltrating glioblastoma of the brain stem in an 8-year-old child; normalization of the pneumoencephalogram after radiotherapy]. Rev. Otoneuroophtalmol. 31, 119\u2013123 (1959).","journal-title":"Rev. Otoneuroophtalmol."},{"key":"4354_CR9","first-page":"1","volume":"107","author":"T Roujeau","year":"2007","unstructured":"Roujeau, T. et al. Stereotactic biopsy of diffuse pontine lesions in children. J. Neurosurg. 107, 1\u20134 (2007).","journal-title":"J. Neurosurg."},{"key":"4354_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00401-014-1272-4","volume":"127","author":"V Caretti","year":"2014","unstructured":"Caretti, V. et al. Human pontine glioma cells can induce murine tumors. Acta Neuropathol. 127, 897\u2013909 (2014).","journal-title":"Acta Neuropathol."},{"key":"4354_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40478-017-0479-8","volume":"5","author":"R Salloum","year":"2017","unstructured":"Salloum, R. et al. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Acta Neuropathol. Commun. 5, 78 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"4354_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11185","volume":"7","author":"H Nikbakht","year":"2016","unstructured":"Nikbakht, H. et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat. Commun. 7, 11185 (2016).","journal-title":"Nat. Commun."},{"key":"4354_CR13","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1200\/JCO.2009.25.5463","volume":"28","author":"M Zarghooni","year":"2010","unstructured":"Zarghooni, M. et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor \u03b1 and poly (ADP-ribose) polymerase as potential therapeutic targets. J. Clin. Oncol. 28, 1337\u20131344 (2010).","journal-title":"J. Clin. Oncol."},{"key":"4354_CR14","doi-asserted-by":"publisher","first-page":"e30313","DOI":"10.1371\/journal.pone.0030313","volume":"7","author":"S Puget","year":"2012","unstructured":"Puget, S. et al. Mesenchymal transition and PDGFRA amplification\/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS ONE 7, e30313 (2012).","journal-title":"PLoS ONE"},{"key":"4354_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/neuonc\/nou330","volume":"17","author":"N Truffaux","year":"2015","unstructured":"Truffaux, N. et al. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro Oncol. 17, 953\u2013964 (2015).","journal-title":"Neuro Oncol."},{"key":"4354_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/neuonc\/noq141","volume":"13","author":"B Geoerger","year":"2011","unstructured":"Geoerger, B. et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing\/refractory brain tumors. Neuro Oncol. 13, 109\u2013118 (2011).","journal-title":"Neuro Oncol."},{"key":"4354_CR17","first-page":"3620","volume":"9","author":"RJ Gilbertson","year":"2003","unstructured":"Gilbertson, R. J. et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin. Cancer Res. 9, 3620\u20133624 (2003).","journal-title":"Clin. Cancer Res."},{"key":"4354_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso, C. S. et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21, 555\u2013559 (2015).","journal-title":"Nat. Med."},{"key":"4354_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ejca.2011.09.021","volume":"48","author":"B Geoerger","year":"2012","unstructured":"Geoerger, B. et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur. J. Cancer 48, 253\u2013262 (2012).","journal-title":"Eur. J. Cancer"},{"key":"4354_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/neuonc\/noq199","volume":"13","author":"IF Pollack","year":"2011","unstructured":"Pollack, I. F. et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 13, 290\u2013297 (2011).","journal-title":"Neuro Oncol."},{"key":"4354_CR21","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","volume":"19","author":"A Broniscer","year":"2013","unstructured":"Broniscer, A. et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin. Cancer Res. 19, 3050\u20133058 (2013).","journal-title":"Clin. Cancer Res."},{"key":"4354_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","volume":"130","author":"D Castel","year":"2015","unstructured":"Castel, D. et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 130, 815\u2013827 (2015).","journal-title":"Acta Neuropathol."},{"key":"4354_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11060-011-0681-7","volume":"106","author":"A Chassot","year":"2012","unstructured":"Chassot, A. et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J. Neurooncol. 106, 399\u2013407 (2012).","journal-title":"J. Neurooncol."},{"key":"4354_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11060-017-2702-7","volume":"137","author":"MJ Lobon-Iglesias","year":"2018","unstructured":"Lobon-Iglesias, M. J. et al. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients? J. Neurooncol. 137, 111\u2013118 (2018).","journal-title":"J. Neurooncol."},{"key":"4354_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.21037\/atm-23-1583","volume":"12","author":"G Rubovszky","year":"2024","unstructured":"Rubovszky, G. The role of everolimus in metastatic breast cancer and possibilities of moving forward\u2014a narrative review. Ann. Transl. Med. 12, 68 (2024).","journal-title":"Ann. Transl. Med."},{"key":"4354_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.23.01838","volume":"42","author":"DA Haas-Kogan","year":"2024","unstructured":"Haas-Kogan, D. A. et al. Everolimus for children with recurrent or progressive low-grade glioma: results from the phase II PNOC001 trial. J. Clin. Oncol. 42, 441\u2013451 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4354_CR27","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1016\/j.ejca.2013.08.006","volume":"49","author":"S Bailey","year":"2013","unstructured":"Bailey, S. et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy\u2014results of a United Kingdom phase II trial (CNS 2007 04). Eur. J. Cancer 49, 3856\u20133862 (2013).","journal-title":"Eur. J. Cancer"},{"key":"4354_CR28","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","volume":"36","author":"LM Hoffman","year":"2018","unstructured":"Hoffman, L. M. et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. J. Clin. Oncol. 36, 1963\u20131972 (2018).","journal-title":"J. Clin. Oncol."},{"key":"4354_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay, A. et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32, 520\u2013537 (2017).","journal-title":"Cancer Cell"},{"key":"4354_CR30","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/ijc.32258","volume":"145","author":"S Mueller","year":"2019","unstructured":"Mueller, S. et al. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma\u2014PNOC003: a report from the Pacific Pediatric Neuro-Oncology Consortium. Int. J. Cancer 145, 1889\u20131901 (2019).","journal-title":"Int. J. Cancer"},{"key":"4354_CR31","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/neuonc\/noaf061","volume":"27","author":"MK Mateos","year":"2025","unstructured":"Mateos, M. K. et al. Germline analysis of an international cohort of pediatric diffuse midline glioma patients. Neuro Oncol. 27, 1849\u20131863 (2025).","journal-title":"Neuro Oncol."},{"key":"4354_CR32","doi-asserted-by":"publisher","first-page":"e170329","DOI":"10.1172\/JCI170329","volume":"134","author":"RJ Duchatel","year":"2024","unstructured":"Duchatel, R. J. et al. PI3K\/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma. J. Clin. Invest. 134, e170329 (2024).","journal-title":"J. Clin. Invest."},{"key":"4354_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-022-00509-4","volume":"4","author":"V Thatikonda","year":"2023","unstructured":"Thatikonda, V. et al. Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nat. Cancer 4, 276\u2013289 (2023).","journal-title":"Nat. Cancer"},{"key":"4354_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Gr\u00f6bner","year":"2018","unstructured":"Gr\u00f6bner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327 (2018).","journal-title":"Nature"},{"key":"4354_CR35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele, C. D. et al. Signatures of copy number alterations in human cancer. Nature 606, 984\u2013991 (2022).","journal-title":"Nature"},{"key":"4354_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher, S. et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science 365, 599\u2013604 (2019).","journal-title":"Science"},{"key":"4354_CR37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/ng.2995","volume":"46","author":"L Zhang","year":"2014","unstructured":"Zhang, L. et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat. Genet. 46, 726\u2013730 (2014).","journal-title":"Nat. Genet."},{"key":"4354_CR38","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1126\/science.1076182","volume":"298","author":"B Wang","year":"2002","unstructured":"Wang, B., Matsuoka, S., Carpenter, P. B. & Elledge, S. J. 53BP1, a mediator of the DNA damage checkpoint. Science 298, 1435\u20131438 (2002).","journal-title":"Science"},{"key":"4354_CR39","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.dnarep.2020.102915","volume":"93","author":"A Shibata","year":"2020","unstructured":"Shibata, A. & Jeggo, P. A. Roles for 53BP1 in the repair of radiation-induced DNA double strand breaks. DNA Repair (Amst.) 93, 102915 (2020).","journal-title":"DNA Repair (Amst.)"},{"key":"4354_CR40","doi-asserted-by":"publisher","first-page":"1231916","DOI":"10.3389\/fimmu.2023.1231916","volume":"14","author":"A Mac Donald","year":"2023","unstructured":"Mac Donald, A. et al. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front. Immunol. 14, 1231916 (2023).","journal-title":"Front. Immunol."},{"key":"4354_CR41","doi-asserted-by":"publisher","first-page":"954","DOI":"10.4149\/neo_2019_190210N112","volume":"66","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Gao, L., Shao, M. & Sun, G. Y. A MYC target long non-coding RNA GATA2-AS1 regulates non-small cell lung cancer growth. Neoplasma 66, 954\u2013962 (2019).","journal-title":"Neoplasma"},{"key":"4354_CR42","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1038\/s41388-023-02798-0","volume":"42","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity. Oncogene 42, 2673\u20132687 (2023).","journal-title":"Oncogene"},{"key":"4354_CR43","doi-asserted-by":"publisher","first-page":"113130","DOI":"10.1016\/j.yexcr.2022.113130","volume":"416","author":"Y Niu","year":"2022","unstructured":"Niu, Y. et al. LncRNA GATA2-AS1 suppresses esophageal squamous cell carcinoma progression via the mir-940\/PTPN12 axis. Exp. Cell Res. 416, 113130 (2022).","journal-title":"Exp. Cell Res."},{"key":"4354_CR44","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","volume":"20","author":"M Snuderl","year":"2011","unstructured":"Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810\u2013817 (2011).","journal-title":"Cancer Cell"},{"key":"4354_CR45","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1101\/gad.184911.111","volume":"26","author":"LA Carvajal","year":"2012","unstructured":"Carvajal, L. A., Hamard, P.-J., Tonnessen, C. & Manfredi, J. J. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes Dev. 26, 1533\u20131545 (2012).","journal-title":"Genes Dev."},{"key":"4354_CR46","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41416-020-01032-y","volume":"123","author":"R Yang","year":"2020","unstructured":"Yang, R. et al. E2F7\u2212EZH2 axis regulates PTEN\/AKT\/mTOR signalling and glioblastoma progression. Br. J. Cancer 123, 1445\u20131455 (2020).","journal-title":"Br. J. Cancer"},{"key":"4354_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40478-024-01837-5","volume":"12","author":"M Motevasseli","year":"2024","unstructured":"Motevasseli, M. et al. Distinct tumor\u2212TAM interactions in IDH-stratified glioma microenvironments unveiled by single-cell and spatial transcriptomics. Acta Neuropathol. Commun. 12, 133 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"4354_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52096-w","volume":"15","author":"AF Andrade","year":"2024","unstructured":"Andrade, A. F. et al. Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function. Nat. Commun. 15, 7769 (2024).","journal-title":"Nat. Commun."},{"key":"4354_CR49","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1111\/cas.15842","volume":"114","author":"A Feng","year":"2023","unstructured":"Feng, A. et al. Homeobox A7 promotes esophageal squamous cell carcinoma progression through C-C motif chemokine ligand 2-mediated tumor-associated macrophage recruitment. Cancer Sci. 114, 3270\u20133286 (2023).","journal-title":"Cancer Sci."},{"key":"4354_CR50","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.1158\/1078-0432.CCR-19-0126","volume":"25","author":"C Werbrouck","year":"2019","unstructured":"Werbrouck, C. et al. TP53 pathway alterations drive radioresistance in diffuse intrinsic pontine gliomas (DIPG). Clin. Cancer Res. 25, 6788\u20136800 (2019).","journal-title":"Clin. Cancer Res."},{"key":"4354_CR51","doi-asserted-by":"publisher","first-page":"e22721","DOI":"10.1097\/MD.0000000000022721","volume":"99","author":"J Park","year":"2020","unstructured":"Park, J., Yea, J. W. & Park, J. W. Hypofractionated radiotherapy versus conventional radiotherapy for diffuse intrinsic pontine glioma: a systematic review and meta-analysis. Medicine (Baltimore) 99, e22721 (2020).","journal-title":"Medicine (Baltimore)"},{"key":"4354_CR52","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1200\/JCO.2015.63.9161","volume":"34","author":"F Andr\u00e9","year":"2016","unstructured":"Andr\u00e9, F. et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J. Clin. Oncol. 34, 2115\u20132124 (2016).","journal-title":"J. Clin. Oncol."},{"key":"4354_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.canlet.2017.04.019","volume":"400","author":"H Miyahara","year":"2017","unstructured":"Miyahara, H. et al. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 400, 110\u2013116 (2017).","journal-title":"Cancer Lett."},{"key":"4354_CR54","first-page":"455","volume":"39","author":"PC Flannery","year":"2018","unstructured":"Flannery, P. C. et al. Preclinical analysis of MTOR complex 1\/2 inhibition in diffuse intrinsic pontine glioma. Oncol. Rep. 39, 455\u2013464 (2018).","journal-title":"Oncol. Rep."},{"key":"4354_CR55","first-page":"OF1","volume":"17","author":"ER Jackson","year":"2023","unstructured":"Jackson, E. R. et al. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma. Cancer Res. 17, OF1\u2013OF17 (2023).","journal-title":"Cancer Res."},{"key":"4354_CR56","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","volume":"13","author":"S Venneti","year":"2023","unstructured":"Venneti, S. et al. Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer Discov. 13, 2370\u20132393 (2023).","journal-title":"Cancer Discov."},{"key":"4354_CR57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/imr.12796","volume":"291","author":"DR Myers","year":"2019","unstructured":"Myers, D. R., Wheeler, B. & Roose, J. P. mTOR and other effector kinase signals that impact T cell function and activity. Immunol. Rev. 291, 134\u2013153 (2019).","journal-title":"Immunol. Rev."},{"key":"4354_CR58","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s43018-022-00403-z","volume":"3","author":"FPB Dubois","year":"2022","unstructured":"Dubois, F. P. B. et al. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat. Cancer 3, 994\u20131011 (2022).","journal-title":"Nat. Cancer"},{"key":"4354_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28198-8","volume":"13","author":"P Khadka","year":"2022","unstructured":"Khadka, P. et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat. Commun. 13, 604 (2022).","journal-title":"Nat. Commun."},{"key":"4354_CR60","doi-asserted-by":"publisher","first-page":"103779","DOI":"10.1016\/j.dnarep.2024.103779","volume":"144","author":"S Kilgas","year":"2024","unstructured":"Kilgas, S., Swift, M. L. & Chowdhury, D. 53BP1-the \u2018Pandora\u2019s box\u2019 of genome integrity. DNA Repair (Amst.) 144, 103779 (2024).","journal-title":"DNA Repair (Amst.)"},{"key":"4354_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02630-8","volume":"19","author":"CJ Pachocki","year":"2022","unstructured":"Pachocki, C. J. & Hol, E. M. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. J. Neuroinflammation 19, 276 (2022).","journal-title":"J. Neuroinflammation"},{"key":"4354_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/neuonc\/noy145","volume":"21","author":"NAP Lieberman","year":"2019","unstructured":"Lieberman, N. A. P. et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 21, 83\u201394 (2019).","journal-title":"Neuro Oncol."},{"key":"4354_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0553-x","volume":"6","author":"GL Lin","year":"2018","unstructured":"Lin, G. L. et al. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol. Commun. 6, 51 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"4354_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49595-1","volume":"15","author":"AB Levine","year":"2024","unstructured":"Levine, A. B. et al. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. Nat. Commun. 15, 5790 (2024).","journal-title":"Nat. Commun."},{"key":"4354_CR65","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","volume":"54","author":"I Liu","year":"2022","unstructured":"Liu, I. et al. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat. Genet. 54, 1881\u20131894 (2022).","journal-title":"Nat. Genet."},{"key":"4354_CR66","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ccell.2020.07.008","volume":"38","author":"C Chung","year":"2020","unstructured":"Chung, C. et al. Integrated metabolic and epigenomic reprograming by H3K27M mutations in diffuse intrinsic pontine gliomas. Cancer Cell 38, 334\u2013349 (2020).","journal-title":"Cancer Cell"},{"key":"4354_CR67","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00401-023-02651-4","volume":"147","author":"L Auffret","year":"2023","unstructured":"Auffret, L. et al. A new subtype of diffuse midline glioma, H3 K27 and BRAF\/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation. Acta Neuropathol. 147, 2 (2023).","journal-title":"Acta Neuropathol."},{"key":"4354_CR68","doi-asserted-by":"publisher","first-page":"115230","DOI":"10.1016\/j.ejca.2025.115230","volume":"217","author":"AD Pearson","year":"2025","unstructured":"Pearson, A. D. et al. Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur. J. Cancer 217, 115230 (2025).","journal-title":"Eur. J. Cancer"},{"key":"4354_CR69","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/neuonc\/nox021","volume":"19","author":"KJ Cohen","year":"2017","unstructured":"Cohen, K. J., Jabado, N. & Grill, J. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol. 19, 1025\u20131034 (2017).","journal-title":"Neuro Oncol."},{"key":"4354_CR70","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"4354_CR71","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/10543406.2015.1052494","volume":"26","author":"J Wu","year":"2016","unstructured":"Wu, J. Single-arm phase II cancer survival trial designs. J. Biopharm. Stat. 26, 644\u2013656 (2016).","journal-title":"J. Biopharm. Stat."},{"key":"4354_CR72","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/neuonc\/nox227","volume":"20","author":"R Calmon","year":"2018","unstructured":"Calmon, R. et al. Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas. Neuro Oncol. 20, 994\u20131002 (2018).","journal-title":"Neuro Oncol."},{"key":"4354_CR73","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ijrobp.2017.04.007","volume":"99","author":"R Calmon","year":"2017","unstructured":"Calmon, R. et al. Multimodal magnetic resonance imaging of treatment-induced changes to diffuse infiltrating pontine gliomas in children and correlation to patient progression-free survival. Int. J. Radiat. Oncol. Biol. Phys. 99, 476\u2013485 (2017).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"4354_CR74","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/nan.12117","volume":"40","author":"MA Idoate","year":"2014","unstructured":"Idoate, M. A., Echeveste, J., Diez-Valle, R., Lozano, M. D. & Aristu, J. Biological and clinical significance of the intratumour heterogeneity of PTEN protein expression and the corresponding molecular abnormalities of the PTEN gene in glioblastomas. Neuropathol. Appl. Neurobiol. 40, 736\u2013746 (2014).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"4354_CR75","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/noz142","volume":"22","author":"P Varlet","year":"2020","unstructured":"Varlet, P. et al. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro Oncol. 22, 116\u2013127 (2020).","journal-title":"Neuro Oncol."},{"key":"4354_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"4354_CR77","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"4354_CR78","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.celrep.2012.12.008","volume":"3","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246\u2013259 (2013).","journal-title":"Cell Rep."},{"key":"4354_CR79","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cell.2013.02.023","volume":"152","author":"JO Korbel","year":"2013","unstructured":"Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226\u20131236 (2013).","journal-title":"Cell"},{"key":"4354_CR80","doi-asserted-by":"publisher","first-page":"e1009557","DOI":"10.1371\/journal.pgen.1009557","volume":"17","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes. PLoS Genet. 17, e1009557 (2021).","journal-title":"PLoS Genet."},{"key":"4354_CR81","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"AR Pombo Antunes","year":"2021","unstructured":"Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595\u2013610 (2021).","journal-title":"Nat. Neurosci."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04354-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:03:33Z","timestamp":1781791413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4354"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04354-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that three drugs (everolimus, erlotinib and dasatinib) were supplied free of charge by the pharmaceutical companies (Novartis, F. Hoffman-La Roche and Bristol Myers Squibb, respectively). Novartis also provided a grant to support the conduct of the study. None of these companies had any influence on the authors\u2019 judgments or actions with regard to the objective presentation, analysis and interpretation of the data. The authors declare no other competing interests related to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}